Compare BAFN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | CTSO |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 45.9M |
| IPO Year | N/A | N/A |
| Metric | BAFN | CTSO |
|---|---|---|
| Price | $6.70 | $0.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 14.0K | ★ 79.8K |
| Earning Date | 01-29-2026 | 03-11-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,595,000.00 | $36,979,520.00 |
| Revenue This Year | N/A | $7.95 |
| Revenue Next Year | N/A | $8.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $5.72 | $0.60 |
| 52 Week High | $19.75 | $1.61 |
| Indicator | BAFN | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 48.34 |
| Support Level | $6.32 | $0.63 |
| Resistance Level | $7.10 | $0.73 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 92.02 | 38.09 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.